Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
45
IOSP Quote, Financials, Valuation and Earnings
Last price:
$89.50
Seasonality move
:
5.77%
Day range:
$86.14 - $89.91
52-week range:
$80.32 - $133.71
Dividend yield:
1.72%
P/E ratio:
64.21x
P/S ratio:
1.22x
P/B ratio:
1.85x
Volume:
277K
Avg. volume:
264.1K
1-year change:
-25.82%
Market cap:
$2.2B
Revenue:
$1.8B
EPS (TTM):
$1.40
Analysts' Opinion
-
Consensus RatingInnospec has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $126.00, Innospec has an estimated upside of 40.16% from its current price of $89.90.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $115.00 representing 100% downside risk from its current price of $89.90.
Fair Value
-
According to the consensus of 1 analyst, Innospec has 40.16% upside to fair value with a price target of $126.00 per share.
IOSP vs. S&P 500
-
Over the past 5 trading days, Innospec has overperformed the S&P 500 by 0.26% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Innospec does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Innospec revenues have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter Innospec reported revenues of $466.8M.
Earnings Growth
-
Innospec earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Innospec reported earnings per share of -$2.82.
Enterprise value:
2B
EV / Invested capital:
--
Price / LTM sales:
1.22x
EV / EBIT:
10.82x
EV / Revenue:
1.06x
PEG ratio (5yr expected):
1.39x
EV / Free cash flow:
16.04x
Price / Operating cash flow:
18.47x
Enterprise value / EBITDA:
8.72x
Gross Profit (TTM):
$542.9M
Return On Assets:
2.05%
Net Income Margin (TTM):
1.93%
Return On Equity:
2.97%
Return On Invested Capital:
2.97%
Operating Margin:
8.01%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $2B | $1.9B | $1.8B | $494.7M | $466.8M | |
| Gross Profit | $586.7M | $591.1M | $542.9M | $155.7M | $136.2M | |
| Operating Income | $187.3M | $161.6M | $181.1M | $39.3M | $37.4M | |
| EBITDA | $223.8M | $200.9M | $224.6M | $49.5M | $48.3M | |
| Diluted EPS | $5.32 | $5.57 | $1.40 | $1.51 | -$2.82 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $566.2M | $728.1M | $872.6M | $885.7M | $956.6M | |
| Total Assets | $1.4B | $1.6B | $1.6B | $1.7B | $1.7B | |
| Current Liabilities | $252.4M | $336.6M | $405.8M | $371.5M | $371.4M | |
| Total Liabilities | $452.5M | $537.9M | $563.3M | $557.8M | $518.6M | |
| Total Equity | $944.9M | $1B | $1B | $1.1B | $1.2B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $81.7M | $207.3M | $184.5M | $72.4M | $25.7M | |
| Cash From Investing | -$42.1M | -$111.8M | -$62M | -$55.8M | -$20.6M | |
| Cash From Financing | -$33.7M | -$39M | -$35.3M | -$20.4M | -$17.8M | |
| Free Cash Flow | $39.4M | $130.1M | $122.2M | $51.2M | $4.9M | |
IOSP
Sector
Market Cap
$2.2B
$18.2M
Price % of 52-Week High
67.24%
62.16%
Dividend Yield
1.72%
0%
Shareholder Yield
1.36%
1.27%
1-Year Price Total Return
-25.82%
-15.57%
Beta (5-Year)
1.028
0.918
Dividend yield:
1.72%
Annualized payout:
$1.55
Payout ratio:
108.99%
Growth streak:
11 years
Technicals
8-day SMA
Buy
Level
$88.66
200-day SMA
Sell
Level
$109.82
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$88.32
Relative Strength Index (RSI14)
Sell
Level
45.62
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-31.44
50-day SMA
Sell
Level
$95.61
MACD (12, 26)
Sell
Level
-1.86
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.8186)
Buy
CA Score
(Annual)
Level (1.2805)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.0571)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Fuel Specialties segment, which generates the majority of revenue, sells products used to improve fuel efficiency, boost engine performance, and reduce emissions for automobiles, boats, and airplanes. It also sells products used by oil field service providers in the extraction of oil and gas. The Performance Chemicals segment sells products to the personal-care industry. The Oilfield Services segment develops and markets products to prevent loss of mud.
Stock Forecast FAQ
In the current month, IOSP has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IOSP average analyst price target in the past 3 months is $126.00.
-
Where Will Innospec Stock Be In 1 Year?
According to analysts, the consensus estimate is that Innospec share price will rise to $126.00 per share over the next 12 months.
-
What Do Analysts Say About Innospec?
Analysts are divided on their view about Innospec share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Innospec is a Sell and believe this share price will drop from its current level to $115.00.
-
What Is Innospec's Price Target?
The price target for Innospec over the next 1-year time period is forecast to be $126.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IOSP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Innospec is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of IOSP?
You can purchase shares of Innospec via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Innospec shares.
-
What Is The Innospec Share Price Today?
Innospec was last trading at $89.50 per share. This represents the most recent stock quote for Innospec. Yesterday, Innospec closed at $89.90 per share.
-
How To Buy Innospec Stock Online?
In order to purchase Innospec stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.48% over the past day.
Buy
53
EAT alert for May 1
Brinker International [EAT] is down 1.82% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 3.3% over the past day.
